Protalix BioTherapeutics (PLX) 10-K2021 FY Annual report

Filed: 31 Mar 22, 7:12am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: al, annum, ascribe, Bookkeeping, boundary, caution, Christoph, CRL, derecognition, disagree, eleva, erythema, explained, FFDCA, ID, Inline, ITT, landscape, multicenter, multinational, occasion, PP, prompt, Rapporteur, Removal, resolution, resubmission, resubmitted, role, sector, unchanged, upcoming, verification, Wainwright, Wanner, worth

Removed: accrue, aggregated, Aharon, aim, analyzed, delivered, discharge, eGRF, FDASIA, recording, return, scheduled, Schwartz, semiannually, setting, Shaaltiel, Yoseph

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PLX transcripts

PLX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-230604 and 333-237736) and on Form S-8 (No. 333-148983, No. 333-182677, No. 333-203960, No. 333-225526 and No. 333 239101) of Protalix BioTherapeutics, Inc. of our report dated March 31, 2022 relating to the financial statements, which appears in this Form 10-K.

X, 2022

Tel-Aviv, Israel

March 31, 2022

/s/ Kesselman & Kesselman

Certified Public Accountants (lsr.)

A member firm of PricewaterhouseCoopers

International Limited

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.